JNJ vs BMY
By Alex · Tickerpine
Johnson & Johnson vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | BMY |
|---|---|---|
| Price | $254.66 | $57.52 |
| Market cap | $613.02B | $117.46B |
| P/E ratio | 29.5 | 16.1 |
| ROE | 26.42% | 38.73% |
| Profit margin | 21.83% | 15.01% |
| Revenue growth | 9.90% | 2.60% |
| Dividend yield | 2.10% | 4.38% |
| Beta | 0.26 | 0.24 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs BMY in plain English
- JNJ is the bigger company — about 5.2× the market cap of BMY.
- BMY is cheaper on earnings (P/E 16.1 vs 29.5).
- BMY earns a higher return on equity (39% vs 26%).
- JNJ is growing revenue faster (10% vs 3%).
- BMY has the higher dividend yield (4.38% vs 2.10%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.